D-serine added to antipsychotics for the treatment of schizophrenia

Biological Psychiatry

Volumn 44, Issue 11, 1998, Pages 1081-1089

  Tsai, Guochuan ^a   Yang, Pinchen ^b   Chung, Li Chen ^b   Lange, Nicholas ^a   Coyle, Joseph T ^a  

^a Lab of Molec and Devmtl Neurosci   (United States)

^b Kaohsiung Medical Center   (Taiwan)

Author keywords

D serine; Glutamate; N methyl D aspartate; Schizophrenia; Treatment

Indexed keywords

CHLORPROMAZINE; DEXTRO SERINE; GLUTAMATE RECEPTOR; HALOPERIDOL; PIPOTIAZINE PALMITATE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; MALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SERINE;

EID: 0032403626     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00279-0     Document Type: Article

References (65)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms. 1983;University of Iowa, Iowa City, IA.
2. Structured Clinical Interview for DSM-IV. 1994;American Psychiatric Press, Washington, DC.
3. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
4. Banerjee S.P., Zuck L.G., Yablonsky-Alter E., Lidsky T.I. Glutamate agonist activity Implications for antipsychotic drug action and schizophrenia . Neuroreport. 6:1995;2500-2504.
5. Barnes T.R.E. A rating scale for the drug-induced akathesia. Br J Psychiatry. 154:1989;672-676.
6. Carone F.A., Nakamura S., Goldman B. Urinary loss of glucose, phosphate, and protein by diffusion into proximal straight tubules injured by D-serine and maleic acid. Lab Invest. 52:1985;605-610.
7. Carpenter W.T., Buchanan R.W. Schizophrenia. N Engl J Med. 330:1994;681-690.
8. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 23:1997;663-673.
9. Contreras P.C. D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology. 29:1990;291-293.
10. Cotman CW, Monaghan DT (1987): Chemistry and anatomy of excitatory amino acid systems. In: Meltzer, HY, editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, pp 451-457.
11. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry. 3:1996;241-253.
12. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., Morihisa J.M. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol. 12:1989;1-13.
13. D'souza D.C., Charney D.S., Krystal J.H. Glycine site agonist of the NMDA receptor A review . CNS Drug Rev. 1:1995;227-260.
14. Fletcher E.J., MacDonald J.F. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurons. Eur J Pharmacol. 235:1993;291-295.
15. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. A dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
16. Goff D.C., Tsai G., Manoach D.S., et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 153:1996;1628-1630.
17. Goff DC, Tsai G, Levitt J, et al (in press): A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry.
18. Grotta J. Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke. 25:1994;255.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;US Department of Health, Education, and Welfare, Washington DC.
20. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia [review]. Clin Neuropharmacol. 18:1995;237-249.
21. Hamilton M. A rating scale of depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
22. Hashimoto A. Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-L-cysteine and o-phthaldialdehyde. J Chromatogr. 582:1992;41-48.
23. Hashimoto A., Oka T. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol. 52:1997;325-353.
24. Hashimoto A., Nishikawa T., Konno R., et al. Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase. Neurosci Lett. 152:1993;33-36.
25. Hashimoto A., Nishikawa T., Oka T., Takahashi K. Endogenous D-serine in rat brain N-methyl-D-aspartate receptor-related distribution and aging . J Neurochem. 60:1993;783-786.
26. Hashimoto A., Oka T., Nishikawa T. Anatomical distribution and postnatal changes in endogenous free D-aspartate and D-serine in rat brain and periphery. Eur J Neurosci. 7:1995;1657-1663.
27. Heresco-Levy U., Javitt D.C., Ermilov M., et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
28. Heresco-Levy U., Silipo G., Javitt D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull. 32:1996;731-740.
29. Herrling P.L. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist Results from animal models and first results in humans . Neuropsychopharmacology. 10:(suppl 3):1994;591S.
30. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 17:1994;31-108.
31. Iwama H., Takahashi K., Kure S., et al. Depletion of cerebral D-serine in non-ketotic hyperglycinemia Possible involvement of glycine cleavage system in control of endogenous D-serine . Biochem Biophys Res Commun. 231:1997;793-796.
32. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
33. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
34. Kane J.M. Clinical efficacy of clozapine in treatment of refractory schizophrenia An overview . Br J Psychiatry. 18:(suppl 17):1992;41-54.
35. Kay S.R., Opler L.A., Fiszbein A. Positive and negative syndrome scale (PANSS) manual. Schizophr Bull. 13:1987;261-276.
36. Kirkpatrick B., Buchanan R., McKenney P. The schedule for the deficit syndrome An instrument for research in schizophrenia . Psychiatry Res. 30:1989;119-123.
37. Kristensen J.D., Svensson B., Gordh T. The NMDA receptor antagonist CPP abolishes neurogenic 'wind up pain' after intrathecal administration in humans. Pain. 51:1992;249-253.
38. Krystal J.H., Karper L.P., Seibyl J.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51:1994;199-214.
39. Kumashiro S., Hashimoto A., Nishikawa T. Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Res. 681:1995;117-125.
40. Leeson P.D., Iversen L.L. The glycine site on the NMDA receptor Structure-activity relationships and therapeutic potential . J Med Chem. 37:1994;4053-4067.
41. Leiderman E., Zylberman I., Zukin S.R., Cooper T.B., Javitt D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia An open-label trial . Biol Psychiatry. 39:1996;213-215.
42. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S. Five factor model of schizophrenia. Initial validation. J Nerv Ment Dis. 182:1994;631-638.
43. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU Side Effect Rating Scale A new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients . Acta Psychiatr Scand Suppl. 334:1987;1-100.
44. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
45. Matsui T., Sikiguchi M., Hashimoto A., et al. Functional comparison of D-serine and glycine in rodents The effect of cloned NMDA receptors and the extracellular concentration . J Neurochem. 65:1995;454-458.
46. Mayer M.L., Vyklicky L., Clements J. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature. 338:1989;425-427.
47. McDonald J.W., Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev. 15:1990;41-70.
48. McNamara D., Dingledine R. Dual effects of glycine on NMDA-induced neurotoxicity in rat cortical cultures. J Neurosci. 10:1990;3970-3976.
49. Nagata Y., Konno R., Niwa A. Amino acid levels in D-alanine-administered mutant mice lacking D-amino acid oxidase. Metabolism. 9:1994;1153-1157.
50. Olney J.W. Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol. 30:1990;41-47.
51. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
52. Schell M.J., Brady R.J., Molliver M.E., Snyder S.H. D-serine as a neuromodulator Regional and developmental localizations in rat brain glia resemble NMDA receptors . J Neurosci. 17:1997;1604-1615.
53. Simpson G.M., Angus J.W.S. Drug-induced extrapyramidal disorders. Acta Psychiatr Scand Suppl. 212:1970;11-19.
54. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:1970;11-19.
55. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G.G. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry. 54:1997;549-557.
56. Tanii Y., Nishikawa T., Hashimoto A., Takahashi K. Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain Res. 563:1991;281-284.
57. Tanii Y., Nishikawa T., Hashimoto A., Takahashi K. Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia. J Pharmacol Exp ther. 269:1994;1040-1048.
58. Thomson A.M., Walker V.E., Flynn D.M. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature. 338:1989;422-424.
59. Tollefson G.D., Beasley C.M., Tran P.V., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders Results of an international collaborative trial . Am J Psychiatry. 154:1997;457-465.
60. Tsai G., Passani L.A., Slusher B.S., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52:1995;829-836.
61. Ulas J., Cotman C.W. Excitatory amino acid receptors in schizophrenia. Schizophr Bull. 19:1993;105-117.
62. van Berckel B.N.M., Hijman R., van der Linder J.A., et al. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 40:1996;1298-1300.
63. Wood P.L., Hawkinson J.E., Goodenough D.B. Formation of D-serine from L-phosphoserine in brain synaptosomes. J Neurochem. 67:1996;1485-1490.
64. Zimbroff D.L., Kane J.M., Tamminga C.A., et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry. 154:1997;782-791.
65. Zylberman I., Javitt D.C., Zukin S.R. Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia. Ann NY Acad Sci. 757:1995;487-491.